Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
[115] RCT	74 children and adolescents aged 7 to 17 years with GAD, separation anxiety disorder, and/or social phobia (47/74 [64%] had GAD either with or without another disorder) In review [114]	Gastrointestinal adverse effects (abdominal pain and nausea) 2 weeks 16/35 (46%) with fluoxetine 7/37 (19%) with placebo	P = 0.04	Effect size not calculated	placebo
[115] RCT	74 children and adolescents aged 7 to 17 years with GAD, separation anxiety disorder, and/or social phobia (47/74 [64%] had GAD either with or without another disorder) In review [114]	Withdrawal from trial with fluoxetine with placebo
[115] RCT	74 children and adolescents aged 7 to 17 years with GAD, separation anxiety disorder, and/or social phobia (47/74 [64%] had GAD either with or without another disorder) In review [114]	Neurological complaints (drowsiness and headaches) 2 weeks 16/36 (44%) with fluoxetine 5/36 (14%) with placebo	P = 0.004	Effect size not calculated	placebo